logo

CELU

Celularity·NASDAQ
--
--(--)
--
--(--)
5.50 / 10
Netural

Fundamental metrics for CELU are mixed (score 5.5/10). Strengths include a healthy gross profit margin (43.4%) and solid revenue-to-market value positioning, yet weaknesses such as a low fixed-assets turnover ratio (0.378) and suboptimal net-profit distribution temper the outlook. Overall, the fundamental stance is neutral, with both supportive and cautionary factors in play.

Fundamental(5.5)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.71
Score3/3
Weight42.65%
1M Return20.82%
Inventory turnover ratio
Value3.19
Score2/3
Weight-3.14%
1M Return-2.63%
Gross profit margin (%)
Value43.42
Score2/3
Weight2.05%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight12.40%
1M Return7.79%
PB-ROE
Value-0.59
Score3/3
Weight19.48%
1M Return11.47%
Current assets turnover ratio
Value1.44
Score2/3
Weight1.45%
1M Return1.15%
Fixed assets turnover ratio
Value0.38
Score1/3
Weight-1.97%
1M Return-1.64%
Asset-MV
Value-0.50
Score1/3
Weight15.03%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight12.42%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.37%
1M Return-0.30%
Is CELU undervalued or overvalued?
  • CELU scores 5.50/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -198.75% net margin, -0.51 P/E ratio, -1.87 P/B ratio, and -175.21% earnings growth, these metrics solidify its Netural investment rating.